Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyAetna Photodynamic Therapy Coverage Update | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0375

    Photodynamic Therapy

    Customize your policy alerts

    Sign up for Aetna Policy 0375 alerts

    Get alerted when Policy 0375 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Aetna Clinical Policy Bulletin (0375) defines medical necessity criteria, investigational/excluded indications, and coding guidance for photodynamic therapy (topical and intravenous photosensitizers) for commercial medical plans. It includes covered indications (esophageal cancer, lung cancer, certain non-melanoma skin tumors, cholangiocarcinoma) with criteria, lists of covered and not-covered CPT/HCPCS/ICD-10 codes, and background/evidence discussion.

    Policy Summary
    PayerAetna
    PolicyPhotodynamic Therapy
    Policy CodePolicy 0375
    Change TypeNo material change
    Effective DateJan 31, 2000
    Last ReviewJun 21, 2023
    Next Review DateApr 11, 2024
    Key ActionProvider must document that the patient's diagnosis and clinical situation meet the listed medical necessity criteria (e.g., obstruction status, Barrett's esophagus ineligible for esophagectomy, inability to use Nd:YAG for esophageal partial obstruction, inoperable cholangiocarcinoma with stenting).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this update.

    4Medically necessary indications listed
    ~40+Investigational/Not covered indications listed
    MultipleCode groups present
    predominantly lowEvidence strength
    2000-2024Policy active period

    Coverage Summary

    This document is Aetna Clinical Policy Bulletin 0375 addressing photodynamic therapy (PDT) for commercial medical plans. Scope: the policy defines medical necessity criteria for specific covered indications (notably certain esophageal cancer, endobronchial non-small cell lung cancer, selected non-melanoma skin tumors using topical photosensitizers, and PDT as an adjunct to stenting for inoperable cholangiocarcinoma), lists investigational/excluded indications (many cancer and non-cancer uses), and provides coding guidance. Policy status is CURRENT with policy number 0375; effective date 2000-01-31; last review date 2023-06-21.

    Photodynamic Therapy - Key Policy Metadata
    PolicyPhotodynamic Therapy
    PayerAetna
    Policy Number0375
    Effective Date2000-01-31
    Last Review
    Policy Summary
    PayerAetna
    PolicyPhotodynamic Therapy
    Policy CodePolicy 0375
    Change TypeNo material change
    Effective DateJan 31, 2000
    Last ReviewJun 21, 2023
    Next Review DateApr 11, 2024
    Key ActionProvider must document that the patient's diagnosis and clinical situation meet the listed medical necessity criteria (e.g., obstruction status, Barrett's esophagus ineligible for esophagectomy, inability to use Nd:YAG for esophageal partial obstruction, inoperable cholangiocarcinoma with stenting).
    SourceLink
    On This Page
    Coverage SummaryMedical-Necessity CriteriaNot Covered / Experimental IndicationsCodingProvider Actions & Billing GuidanceBackground & Evidence SummaryDefinitionsRevision History
    2023-06-21
    Next Review2024-04-11
    Coverage stancemixed
    Medically necessary indications listed4

    Medical-Necessity Criteria

    Esophageal Cancer - Medical Necessity

    Covered when ANY of the following are met:

    ANY of the following

    • Barrett's esophagus carcinoma in-situ and high-grade disease in members who are not candidates for esophagectomy.
    • Completely obstructing esophageal cancer.
    • Partially obstructing esophageal cancer, in members who cannot be satisfactorily treated with Nd:YAG laser therapy.

    Lung Cancer (endobronchial non-small cell) - Medical Necessity

    Covered when ANY of the following are met:

    ANY of the following

    • Completely obstructing endobronchial non-small cell lung cancer.
    • Microinvasive endobronchial non-small cell lung cancer at an early stage, for whom surgery and radiotherapy are not indicated.
    • Partially obstructing endobronchial non-small cell lung cancer.

    Non-melanoma Skin Tumors - Medical Necessity (topical photosensitizers)

    ONE of

    • Basal cell carcinoma.
    • Cutaneous lesions of Bowen's disease (carcinoma in situ of skin).
    • Refractory actinic keratoses.

    Other covered skin indications using specified agents

    • Photodynamic therapy using methyl aminolevulinate for low-risk squamous cell carcinoma in-situ where surgery or radiation is contraindicated or impractical.
    • Photodynamic therapy using aminolevulinic acid or methyl aminolevulinate for erythroplasia of Queyrat.

    Not covered with intravenous photosensitizers for skin indications

    Cholangiocarcinoma - Medical Necessity

    Covered when used as an adjunct:

    ALL of the following

    • Photodynamic therapy used as an adjunct to stenting for palliation of inoperable cholangiocarcinoma.

    Background Evidence Summaries

    • Photodynamic therapy (PDT) uses a photosensitizing agent activated by light to produce reactive oxygen species that destroy targeted tissue. Agents include intravenous porfimer sodium (Photofrin) for internal malignancies and topical aminolevulinic acid or methyl aminolevulinate for cutaneous lesions.
    • For esophageal and endobronchial tumors, PDT has been used for palliation of obstructing lesions and for treatment of superficial or microinvasive disease when surgery or radiotherapy are not options; evidence includes case series and nonrandomized studies demonstrating symptomatic relief and tumor ablation, though randomized comparative data are limited.
    • For non-melanoma skin tumors, topical PDT with aminolevulinic acid or methyl aminolevulinate has demonstrated efficacy for superficial basal cell carcinoma, Bowen's disease, refractory actinic keratoses, and selected in-situ squamous cell carcinomas when other treatments are contraindicated or impractical; outcomes include lesion clearance and cosmetic benefits in multiple clinical trials and systematic reviews.
    • For cholangiocarcinoma, small randomized and nonrandomized studies suggest PDT combined with biliary stenting can improve biliary drainage and may prolong survival or quality of life compared with stenting alone, supporting its role as an adjunct for palliation in inoperable cases.

    Not Covered / Experimental Indications

    Experimental and Investigational - Cancer Indications (Not Covered)

    PDT is considered experimental and investigational for ANY of the following cancer indications:

    ANY of the following

    • Brain tumors (e.g., glioma)
    • Breast cancer
    • Cervical intraepithelial neoplasia/cervical cancer
    • Colon cancer
    • Gastric cancer
    • Intra-ocular choroidal metastases
    • Mediastinal carcinoid tumor
    • Mycosis fungoides
    • Pancreatic cancer
    • Pleural mesothelioma
    • Peritoneal carcinomatosis
    • Prostate cancer (interstitial motexafin lutetium-mediated PDT)
    • Retinal hamartomas/tuberous sclerosis
    • Squamous cell carcinoma in the head and neck
    • Squamous dysplasia of the oral cavity
    • Uveal melanoma

    Experimental and Investigational - Non-Cancer Indications (Not Covered)

    PDT is considered experimental and investigational for ANY of the following non-cancer indications:

    ANY of the following

    • Actinic cheilitis
    • Actinic dermatitis
    • Atopic dermatitis (eczematous dermatitis)
    • Central serous chorioretinopathy
    • Chronic rhinosinusitis
    • Chronic ulcers (including diabetic ulcers)

    Coding

    CPT codes covered if selection criteria are met (endoscopic Photofrin PDT)CPTCovered
    96570Photodynamic therapy by endoscopic application of light to ablate abnormal tissue via activation of photosensitive drug(s); first 30 minutes (list separately in addition to code for endoscopy or bronchoscopy procedures of lung and esophagus).
    96571Photodynamic therapy by endoscopic application of light to ablate abnormal tissue via activation of photosensitive drug(s); each additional 15 minutes (list separately in addition to code for endoscopy or bronchoscopy procedures of lung and esophagus).
    HCPCS / J-codes covered if selection criteria are met (porfimer sodium and topical ALA/MAL)HCPCS|NDC|mixedCovered
    J9600Porfimer sodium, 75 mg.
    J7308Aminolevulinic acid HCL for topical administration, 20%, single unit dosage form (354 mg).
    J7345Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg.
    CPT codes covered if selection criteria are met (external/topical PDT)CPTCovered
    96567Photodynamic therapy by external application of light to destroy pre-malignant and/or malignant lesions of the skin and adjacent mucosa (e.g., lip) by activation of photosensitive drug(s) each phototherapy exposure session.
    96573Photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care professional, per day.
    96574Debridement of premalignant hyperkeratotic lesion(s) followed with Photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care professional, per day.
    Other related CPT codes (procedures that may accompany PDT)CPT
    31641Bronchoscopy (rigid or flexible); with destruction of tumor or relief of stenosis by any method other than excision (e.g., laser therapy, cryotherapy).
    43228Esophagoscopy, rigid or flexible; with ablation of tumor(s), polyp(s), or other lesion(s), not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique.
    43229Esophagoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed).
    43270Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed).
    43278ERCP; with ablation of tumor(s), polyp(s), or other lesion(s), including pre- and post-dilation and guide wire passage, when performed.
    43272ERCP; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique.
    HCPCS / J-codes not covered (discontinued or not covered for listed indications)HCPCSNot Covered
    J7309Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 gram [product discontinued].
    ICD-10 codes covered when selection criteria are met (esophagus, lung, skin, cholangiocarcinoma)ICD-10Covered
    C15.3 - C15.9Malignant neoplasm of esophagus [obstructing].
    C34.00 - C34.92Malignant neoplasm of bronchus and lung [microinvasive endobronchial non-small cell] [obstructing].
    D00.1Carcinoma in situ of esophagus [Barrett's].
    C44.01Basal cell carcinoma (covered when criteria met).
    C44.111 - C44.119Basal cell carcinoma codes (covered when criteria met).
    C44.211 - C44.219Basal cell carcinoma codes (covered when criteria met).
    C44.310 - C44.319Basal cell carcinoma codes (covered when criteria met).
    C44.510 - C44.519Basal cell carcinoma codes (covered when criteria met).
    C44.611 - C44.619Basal cell carcinoma codes (covered when criteria met).
    C44.711 - C44.719Basal cell carcinoma codes (covered when criteria met).
    1–10 of 16
    1/2
    ICD-10 codes not covered for indications listed in CPB (examples, not all-inclusive)ICD-10Not Covered
    C43.0 - C43.9Malignant melanoma and melanoma in situ of skin (not covered).
    D03.0 - D03.9Melanoma in situ (not covered).
    A63.0Anogenital (venereal) warts.
    B00.1Herpesviral vesicular dermatitis.
    B07.0Plantar wart.
    B07.8Other viral warts [verrucous vulgaris of the face].
    B35.0, B35.1, B35.3, B35.6Dermatophytosis (superficial mycosis).
    B36.0Pityriasis versicolor [superficial mycosis].
    B97.7Papillomavirus as the cause of diseases classified elsewhere.
    C21.0Malignant neoplasm of anus.
    1–10 of 46
    1/5

    Provider Actions & Billing Guidance

    Documentation Required

    Demonstrate criteria for covered indications

    Document in the medical record that the patient's diagnosis and clinical situation meet the policy's medical necessity criteria. Include specifics that map to covered indications such as obstruction status (completely or partially obstructing lesions), Barrett's esophagus when the patient is not a candidate for esophagectomy, inability to use Nd:YAG laser therapy for partially obstructing esophageal cancer, or inoperable cholangiocarcinoma being treated adjunctively with stenting.

    • Completely or partially obstructing esophageal cancer; note if Nd:YAG is not an option
    • Barrett's esophagus carcinoma in-situ / high-grade disease in patients not candidates for esophagectomy
    • Inoperable cholangiocarcinoma receiving PDT as an adjunct to stenting
    Billing Rule

    Report endoscopic PDT codes in addition to endoscopy/bronchoscopy

    When performing endoscopic PDT procedures of the lung or esophagus, report the PDT time-based CPT codes separately in addition to the code for the endoscopy or bronchoscopy procedure. These codes are listed in the policy and should be billed separately from the scope procedure.

    • 96570
    • 96571
    • Report 96570/96571 in addition to the endoscopy/bronchoscopy procedure code
    Billing Rule

    Topical PDT per day/session coding

    For external (topical) PDT of skin and adjacent mucosa, use the CPT codes designated for external photodynamic therapy; note that two of these codes are reported per day when applicable.

    • 96567
    • 96573
    • 96574
    • 96573 and 96574 are reported per day
    Billing Rule

    Drug coding for photosensitizers

    Use the HCPCS/J-codes specified for photosensitizing agents when selection criteria for coverage are met. Include the intravenous porfimer sodium code and the topical aminolevulinic acid product codes as applicable and distinguish topical versus systemic usage per policy.

    • J9600
    • J7308
    • J7345
    • Note: topical photosensitizers (J7308, J7345) are for topical ALA/MAL; J9600 is porfimer sodium (systemic)
    Documentation Required

    Policy effective and review dates

    Include the policy effective date, the most recent review date, and the scheduled next review in documentation and when checking policy applicability.

    • Effective date: 2000-01-31
    • Last review date: 2023-06-21
    • Next review date: 2024-04-11

    Background & Evidence Summary

    Background: The FDA has approved porfimer sodium (Photofrin) with specified laser systems for treatment of early-stage microinvasive lung cancer and for palliation/relief of obstruction in completely or partially obstructing endobronchial non-small cell lung cancer. PDT has been evaluated as an alternative to esophagectomy for Barrett's esophagus and as adjunctive palliation with stenting for unresectable cholangiocarcinoma, with randomized trials reporting improved survival in some studies. For superficial non-melanoma skin cancers, topical photosensitizers (e.g., ALA, MAL) have evidence of effectiveness; systemic (intravenous) photosensitizers for skin indications are generally avoided because they can cause prolonged photosensitivity.

    Background evidence summaries (major themes):

    • Dermatologic/pre-malignant skin lesions: multiple systematic reviews and RCTs report PDT efficacy for Bowen disease (pooled clearance ~76%) and more limited/heterogeneous results for cutaneous SCC (pooled clearance ~51%) and nodular BCC (higher recurrence vs excision but better cosmetic outcomes).

    • Wound healing and antimicrobial effects: systematic reviews of human and animal studies suggest PDT can reduce bacterial counts, stimulate fibroblasts and collagen, and accelerate healing, but data are heterogeneous and largely from small or preclinical studies.

    • Endodontic/periodontal infections and peri-implant disease: multiple meta-analyses and systematic reviews report mixed or limited benefit of adjunctive antimicrobial PDT (aPDT) with some short-term microbial load reductions and small clinical gains; high heterogeneity and limited high-quality RCTs.

    • Cervical intraepithelial neoplasia/HPV: meta-analysis of RCTs showed increased complete response and HPV clearance with PDT (ORs reported) but overall evidence quality rated very low and higher adverse event rates were observed.

    • Oral leukoplakia and other oral premalignant lesions: systematic reviews indicate PDT may be useful as a non-surgical option with variable complete/partial response rates and need for standardized PDT parameters and more RCTs.

    • Ophthalmologic indications (e.g., chronic central serous chorioretinopathy, wet AMD combinations): trials/meta-analyses show short-term benefits (e.g., reduced subretinal fluid, fewer injections when combined therapy used) but mixed effects on vision outcomes and limited long-term data.

    • Actinic cheilitis and other cutaneous precancerous conditions: case series and systematic reviews report clinical responses with variable histologic cure; daylight-PDT may be better tolerated; evidence limited and heterogeneous.

    • Other indications (lichen sclerosus, herpes labialis, dyspigmentation/photoaging/scarring, chronic rhinosinusitis, SARS-CoV-2 inactivation, peritoneal carcinomatosis, mesothelioma, brain tumors, extra-mammary Paget's disease, peri-implantitis): substantial literature exists but consists largely of small studies, case series, or preclinical data; many uses remain investigational with predominantly low-quality, heterogeneous evidence and a need for larger, well-designed RCTs.

    Study / TopicKey finding
    Ortner et al (2003) RCT for cholangiocarcinoma
    PDT + stenting prolonged median survival: 493 days vs 98 days (p < 0.0001)
    Zoepf et al (2005) RCT (phase IIb) for cholangiocarcinoma
    Median survival 21 months with PDT vs 7 months control (p = 0.0109); higher cholangitis rate in PDT group
    Rhodes et al (2007) RCT MAL-PDT vs excision for nodular BCC
    5-year recurrence 14% MAL-PDT vs 4% excision; cosmetic outcomes better with PDT
    Zhang 2018 meta-analysis (CIN/HPV pooled ORs)
    PDT increased complete response: OR 2.51 for CIN and OR 3.82 for HPV; higher AE rate (OR 13.32); overall evidence very low
    Yongpisarn 2022 pooled clearance (Bowen disease / cSCC)
    Pooled clearance: Bowen disease 76% (95% CI: 71%–80%); cutaneous SCC 51% (95% CI: 35%–66%)
    References count: 163+

    Definitions

    Definitions:

    PDT — Photodynamic therapy: light-based therapy following administration of a photosensitizing agent to induce localized tissue necrosis or antimicrobial effect.

    Revision History

    2000-01-31Effective Date

    Policy effective date as listed in the Clinical Policy Bulletin.

    2023-06-21Last ReviewLatest

    Most recent policy review date listed in the Clinical Policy Bulletin.

    2024-04-11Next Review

    Next scheduled policy review date as listed in the Clinical Policy Bulletin.

    • Photodynamic therapy using intravenous photosensitizers (e.g., porfimer sodium) for the skin indications listed above is considered experimental and investigational.
  1. PDT is considered experimental and investigational for numerous other cancer and non-cancer indications due to insufficient or conflicting evidence regarding effectiveness. Safety considerations include photosensitivity reactions, procedure-related local tissue injury, and potential need for repeat treatments; agent- and indication-specific adverse effects are described in the literature.
  2. Condyloma (genital warts)
  3. Darier's disease (keratosis follicularis)
  4. Disseminated superficial actinic porokeratosis
  5. Dyspigmentation
  6. Endodontic infections
  7. Extra-mammary Paget's disease (e.g., Paget's disease of the vulva)
  8. Granulomatous dermatitis
  9. Halitosis
  10. Herpes labialis
  11. Hidradenitis suppurativa
  12. Human papilloma virus infection
  13. Liposclerosis (lipodermatosclerosis)
  14. Keratitis
  15. Nekam's disease (keratosis lichenoides chronica)
  16. Onychomycosis
  17. Oral leucoplakia / leukoplakia
  18. Oral lichen planus
  19. Peri-implantitis / peri-implant mucositis
  20. Periodontitis
  21. Photoaging
  22. Plantar wart
  23. Psoriasis
  24. Radiation retinopathy
  25. Respiratory papillomatosis
  26. Rosacea
  27. SARS-CoV-2 (COVID-19)
  28. Scarring
  29. Sebaceous hyperplasia
  30. Superficial mycosis
  31. Type II diabetes mellitus
  32. Verrucous vulgaris (common wart) of the face
  33. Vulvar lichen sclerosus
  34. Wound healing